Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ARCAGY/ GINECO GROUP
The Main objective of this study is to evaluate the faisibility of chemotherapy with Paraplatin in combination with Taxol in patients of 70 years or older with epithelial ovary cancer F.I.G.O. stages III and IV and to determine principal predictive factors of this feasibility.
Age
70–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histological or cytological proven diagnosis of epithelial ovary cancer F.I.G.O stages III or IV (when only cytological proven diagnosis is available: malignant cells and pelvis tumoral mass and increased CA-125 must be diagnosed simultaneously)
Patient aged \> 70 years
Neutrophil polynuclears \> 1500/mm3 and Platelets \> 100 000/mm3
No clinical icterus
Life expectancy of at least 3 months
You may not be if
Previous diagnosis of malignancy
Previous chemotherapy treatment
Previous radiotherapy
Hypersensitivity to products containing Cremophore EL
Clareo Health | Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV
